Novel HIV vaccine approach shows promise in “landmark” trial
Progress towards development of an HIV vaccine: report of the AIDS
HIV Vaccines
Infographic—Progress Toward an HIV Vaccine
Experimental HIV Vaccine Elicits Broadly Neutralizing Antibodies
VIDEO
Dr. William Brumskine on HIV Vaccine Research
Progress with HIV vaccine research and development: William Brumskine
KEMRI Gets Sh7 Billion Funding To Develop HIV/AIDS Vaccine
Community Conversation: National Women & Girls HIV/AIDS Awareness Day
Novel HIV Vaccine Research and Development
SA-led HIV vaccination research programme receives R860m grant
COMMENTS
Current approaches to HIV vaccine development: a narrative review
Many technologic advances and research capabilities of the HIV vaccine field have been leveraged rapidly to develop highly successful SARS‐CoV‐2 vaccines; however, among HIV vaccine efficacy trials completed to date, the RV144 Thai trial remains the only study to demonstrate a positive signal with an estimated efficacy of 31% at 3.5 years ...
HIV vaccinology: 2021 update
HIV is a virus that remains a major health concern and results in an infection that has no cure even after over 30 years since its discovery. As such, HIV vaccine discovery continues to be an area of intensive research. In this review, we summarize the most recent HIV vaccine efficacy trials, clinical trials initiated within the last 3 years ...
An HIV Vaccine
Video. An HIV Vaccine — Challenges and Prospects: An Interview with Dr. Anthony Fauci 9m 6s. Now well into the third decade of the pandemic of human immunodeficiency virus (HIV) and AIDS, we ...
HIV Vaccinology: 2021 Update
1. Introduction. Much has happened in the field of human immunodeficiency virus-1 (HIV) vaccine research in recent years. The field of vaccinology has advanced considerably in the last decade, giving rise to novel vaccines for human pathogens. HIV is a pathogen that has challenged vaccine researchers for over 30 years.
Current approaches to HIV vaccine development: a narrative review
Introduction: The development of an effective vaccine to protect against HIV is a longstanding global health need complicated by challenges inherent to HIV biology and to the execution of vaccine efficacy testing in the context of evolving biomedical prevention interventions. This review describes lessons learnt from previous efficacy trials, highlights unanswered questions, and surveys new ...
Prevention, treatment and cure of HIV infection
Most HIV vaccines are designed to induce HIV antibodies. As many standard HIV diagnostic tests target antibodies, vaccinated people might have a positive HIV test even in the absence of any infection.
Research priorities for an HIV cure: International AIDS ...
Fidler, S. et al. HIV cure research in the time of COVID-19 — antiretroviral therapy treatment interruption trials: a discussion paper. J. Virus Erad. 7 , 100025 (2021).
mRNA vaccines offer hope for HIV
117 Altmetric. Metrics. mRNA technology may be uniquely positioned to tackle a major hurdle for HIV vaccines: the elicitation of broadly cross-reactive neutralizing antibodies. A preclinical study ...
NIH launches clinical trial of three mRNA HIV vaccines
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial evaluating three experimental HIV vaccines based on a messenger RNA (mRNA) platform—a technology used in several approved COVID-19 vaccines. NIAID is sponsoring the study, called HVTN 302, and the ...
HIV Vaccine Research: The Way Forward
As research on the natural history of HIV disease progressed, a greater appreciation of the role of T cells in the control of HIV disease progression evolved (5, 6).The immune response elicited by a successful vaccine likely will require both antibodies and T cells that recognize diverse strains of HIV and that reach the site of infection very quickly before infection becomes irreversibly ...
Four Decades of HIV/AIDS
Interview with Dr. Anthony Fauci on progress made during the past four decades of the HIV/AIDS pandemic and ongoing efforts to end this threat. 18m 44s Download. The dramatic saga of the acquired ...
First-in-human clinical trial confirms novel HIV vaccine approach
NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of ...
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and ...
[PDF] HIV Vaccine Research: The Way Forward
Progress and challenges in HIV vaccine research, the priorities arising from a recent summit at NIAID, and the actions needed, some already under way, to address those priorities are summarized. The need to broaden research directed at answering fundamental questions in HIV vaccine discovery through laboratory, nonhuman primate (NHP), and clinical research has recently been emphasized.
Vaccine Research
HIV Vaccine Research Update with Dr. Dieffenbach from CROI 2023. 02-22-2023 The ongoing search for an HIV vaccine was among the topics discussed during the 2023 Conference on Retroviruses and Opportunistic Infections (CROI). HIV.gov spo….
PDF The Repeated Setbacks of Hiv Vaccine Development Laid the National
It is already widely acknowledged that HIV-related research and, in particular, HIV vaccine-related research, have had substantial spillover effects.1 Our thesis is more pointed. We contend that the repeated failures of HIV vaccine trials have served as a critical stimulus to the development of successful vaccine technologies today.
Targeting B cells
In a recent paper in Molecular Therapy , Dr. Christopher Peterson and his team assessed disrupting BCFs as a novel HIV treatment strategy in a non-human primate model of HIV infection. To disrupt BCFs they made use of chimeric antigen receptor (CAR) T cells which are engineered to recognize molecules on the surface of B cells by introducing a ...
COVID-19 Vaccine Hesitancy Among People Living with HIV: A ...
Vaccine hesitancy is one of the top 10 threats to global health, which affects the prevalence and fatality of vaccine-preventable diseases over the world. During the COVID-19 pandemic, people living with HIV (PLWH) may have higher risks of infection, more serious complications, and worse prognosis without the protection of the COVID-19 vaccine. A systematic review and meta-analysis aiming to ...
An HIV Vaccine
A safe and effective HIV vaccine would be an enormously valuable tool in the campaign to stop the spread of HIV. ... Basic research on the HIV envelope has since provided several clues in the ...
New Findings Point to a Promising HIV Vaccine Research Path
A new potential target for HIV vaccine research. Instead, BMC's findings indicate that ADCC could be a potential new target for future vaccine research. ADCC, more than neutralizing antibodies, associates with lower mother-to-child transmission and decreased post-infection infant morbidity. Therefore, the researchers recommend that HIV ...
Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to
Semantic Scholar extracted view of "Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo." ... This review focuses on the research into HIV-1 TAT-derived cell-penetrating peptide over the last years, and discusses TAT's structural features, functions and ...
Advancing an HIV vaccine; advancing vaccinology
Of any pathogen, HIV provides perhaps the greatest challenge to successful vaccine development. Nevertheless, progress continued to be made in 2018; new vaccine concepts entered the clinic and new insights were obtained in basic research that will ultimately help to guide rational vaccine design against many'difficult' pathogens.
The role of correlates of protection in overcoming barriers to vaccine
Supporting research into discovery and use CoP data has the potential to improve go/no-go decision making in clinical development, allow rationale design of new or improved vaccines, reduce the ...
Long-Acting Drugs May Revolutionize H.I.V. Prevention and Treatment
April 17, 2024. A pill taken once a week. A shot administered at home once a month. Even a jab given at a clinic every six months. In the next five to 10 years, these options may be available to ...
Microorganisms
CCR5 and CCL5 are part of a correlated axis of immune pathways used for effective protection against the HIV-1 virus. The purpose of this paper was to review the literary knowledge about the immunopathological relationship between this immune complex and neuroAIDS. ... Vaccine 2008, 26, 3008-3015 ... Our research has shown that HIV infection ...
New vaccine strategy may mean the end of the line for endless boosters
In 2013, the same research team published a paper showing that flu infections also induce us to produce RNAi molecules. "That's why our next step is to use this same concept to generate a flu ...
HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development
Decades of foundational research and investments into HIV biology, though yet to yield an authorized or approved vaccine for HIV/AIDS, have now paid dividends in the rapid development of safe and effective SARS-CoV-2 vaccines. This latter success presents an opportunity for feedback on improved pathways for development of safe and efficacious ...
IMAGES
VIDEO
COMMENTS
Many technologic advances and research capabilities of the HIV vaccine field have been leveraged rapidly to develop highly successful SARS‐CoV‐2 vaccines; however, among HIV vaccine efficacy trials completed to date, the RV144 Thai trial remains the only study to demonstrate a positive signal with an estimated efficacy of 31% at 3.5 years ...
HIV is a virus that remains a major health concern and results in an infection that has no cure even after over 30 years since its discovery. As such, HIV vaccine discovery continues to be an area of intensive research. In this review, we summarize the most recent HIV vaccine efficacy trials, clinical trials initiated within the last 3 years ...
Video. An HIV Vaccine — Challenges and Prospects: An Interview with Dr. Anthony Fauci 9m 6s. Now well into the third decade of the pandemic of human immunodeficiency virus (HIV) and AIDS, we ...
1. Introduction. Much has happened in the field of human immunodeficiency virus-1 (HIV) vaccine research in recent years. The field of vaccinology has advanced considerably in the last decade, giving rise to novel vaccines for human pathogens. HIV is a pathogen that has challenged vaccine researchers for over 30 years.
Introduction: The development of an effective vaccine to protect against HIV is a longstanding global health need complicated by challenges inherent to HIV biology and to the execution of vaccine efficacy testing in the context of evolving biomedical prevention interventions. This review describes lessons learnt from previous efficacy trials, highlights unanswered questions, and surveys new ...
Most HIV vaccines are designed to induce HIV antibodies. As many standard HIV diagnostic tests target antibodies, vaccinated people might have a positive HIV test even in the absence of any infection.
Fidler, S. et al. HIV cure research in the time of COVID-19 — antiretroviral therapy treatment interruption trials: a discussion paper. J. Virus Erad. 7 , 100025 (2021).
117 Altmetric. Metrics. mRNA technology may be uniquely positioned to tackle a major hurdle for HIV vaccines: the elicitation of broadly cross-reactive neutralizing antibodies. A preclinical study ...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a Phase 1 clinical trial evaluating three experimental HIV vaccines based on a messenger RNA (mRNA) platform—a technology used in several approved COVID-19 vaccines. NIAID is sponsoring the study, called HVTN 302, and the ...
As research on the natural history of HIV disease progressed, a greater appreciation of the role of T cells in the control of HIV disease progression evolved (5, 6).The immune response elicited by a successful vaccine likely will require both antibodies and T cells that recognize diverse strains of HIV and that reach the site of infection very quickly before infection becomes irreversibly ...
Interview with Dr. Anthony Fauci on progress made during the past four decades of the HIV/AIDS pandemic and ongoing efforts to end this threat. 18m 44s Download. The dramatic saga of the acquired ...
NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of ...
In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and ...
Progress and challenges in HIV vaccine research, the priorities arising from a recent summit at NIAID, and the actions needed, some already under way, to address those priorities are summarized. The need to broaden research directed at answering fundamental questions in HIV vaccine discovery through laboratory, nonhuman primate (NHP), and clinical research has recently been emphasized.
HIV Vaccine Research Update with Dr. Dieffenbach from CROI 2023. 02-22-2023 The ongoing search for an HIV vaccine was among the topics discussed during the 2023 Conference on Retroviruses and Opportunistic Infections (CROI). HIV.gov spo….
It is already widely acknowledged that HIV-related research and, in particular, HIV vaccine-related research, have had substantial spillover effects.1 Our thesis is more pointed. We contend that the repeated failures of HIV vaccine trials have served as a critical stimulus to the development of successful vaccine technologies today.
In a recent paper in Molecular Therapy , Dr. Christopher Peterson and his team assessed disrupting BCFs as a novel HIV treatment strategy in a non-human primate model of HIV infection. To disrupt BCFs they made use of chimeric antigen receptor (CAR) T cells which are engineered to recognize molecules on the surface of B cells by introducing a ...
Vaccine hesitancy is one of the top 10 threats to global health, which affects the prevalence and fatality of vaccine-preventable diseases over the world. During the COVID-19 pandemic, people living with HIV (PLWH) may have higher risks of infection, more serious complications, and worse prognosis without the protection of the COVID-19 vaccine. A systematic review and meta-analysis aiming to ...
A safe and effective HIV vaccine would be an enormously valuable tool in the campaign to stop the spread of HIV. ... Basic research on the HIV envelope has since provided several clues in the ...
A new potential target for HIV vaccine research. Instead, BMC's findings indicate that ADCC could be a potential new target for future vaccine research. ADCC, more than neutralizing antibodies, associates with lower mother-to-child transmission and decreased post-infection infant morbidity. Therefore, the researchers recommend that HIV ...
Semantic Scholar extracted view of "Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo." ... This review focuses on the research into HIV-1 TAT-derived cell-penetrating peptide over the last years, and discusses TAT's structural features, functions and ...
Of any pathogen, HIV provides perhaps the greatest challenge to successful vaccine development. Nevertheless, progress continued to be made in 2018; new vaccine concepts entered the clinic and new insights were obtained in basic research that will ultimately help to guide rational vaccine design against many'difficult' pathogens.
Supporting research into discovery and use CoP data has the potential to improve go/no-go decision making in clinical development, allow rationale design of new or improved vaccines, reduce the ...
April 17, 2024. A pill taken once a week. A shot administered at home once a month. Even a jab given at a clinic every six months. In the next five to 10 years, these options may be available to ...
CCR5 and CCL5 are part of a correlated axis of immune pathways used for effective protection against the HIV-1 virus. The purpose of this paper was to review the literary knowledge about the immunopathological relationship between this immune complex and neuroAIDS. ... Vaccine 2008, 26, 3008-3015 ... Our research has shown that HIV infection ...
In 2013, the same research team published a paper showing that flu infections also induce us to produce RNAi molecules. "That's why our next step is to use this same concept to generate a flu ...
Decades of foundational research and investments into HIV biology, though yet to yield an authorized or approved vaccine for HIV/AIDS, have now paid dividends in the rapid development of safe and effective SARS-CoV-2 vaccines. This latter success presents an opportunity for feedback on improved pathways for development of safe and efficacious ...